Key facts
- It has raised $4.0M across 1 recorded rounds; the latest was Seed Round ($3.0M) in Dec 2017.
- Notable investors include National Institutes of Health, Connecticut Innovations, United States Department of Agriculture, National Institute of Diabetes and Digestive and Kidney Diseases, U.S. Department of Health and Human Services — 6 tracked in total.
- Mitotherapeutix has filed 4 Form Ds with the SEC since 2016, most recently May 2025 ($3.0M sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Mitotherapeutix
Funding rounds
1 roundsAbout Mitotherapeutix
Developer of molecule-based drugs designed for the treatment of cancer and degenerative liver disorders. The company's drugs are used for the treatment of diseases that can be targeted by modifying or influencing metabolic pathways in the cell, as well as helping to disrupt or correct the metabolic processes, enabling physicians to combat critical conditions associated with the kidney, liver, and the immune system.
- Sector
- Healthcare
- HQ
- Farmington, CT, United States
- Founded
- 2014
- Employees
- 7
- Website
- mitotherapeutix.com/
- Ownership
- Privately Held (backing)
Mitotherapeutix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mitotherapeutix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mitotherapeutix in its N-PORT filings yet. We sweep new filings monthly.